rethinkTHC Search
Menu
Study breakdown

NIDA Leaders Highlight Major Gaps in Cannabis Research Despite Decades of Study

ReviewStrong evidence
The takeaway

A perspective from NIDA leaders identifies critical research gaps in cannabis science, including the effects of high-THC products, consequences of exposure during brain development, and how to leverage the endocannabinoid system for therapeutics.

Cannabis researchers, funding agencies, and policymakers

Cannabis use expanded across all US demographics except adolescents

What the researchers found

Despite decades of cannabis pharmacology research, major knowledge gaps remain in: (1) enduring consequences of cannabis exposure during critical brain development windows, (2) effects of large daily doses of high-THC cannabis, (3) therapeutic opportunities from endocannabinoid system manipulation, and (4) strategies to treat cannabis use disorder and cannabis toxicity.

Why it matters

Coming from the leadership of the US federal agency responsible for drug abuse research, this article sets the agenda for future cannabis science. The identified gaps have direct implications for funding priorities and policy decisions.

The numbers in context

Cannabis legalization has expanded use across all US demographics except adolescents. Multiple targets identified for endocannabinoid system manipulation. Research gaps span developmental neuroscience, high-dose effects, therapeutics, and treatment.

How the study worked

Perspective article from the Director and Deputy Director of the National Institute on Drug Abuse, highlighting research priorities and knowledge gaps in cannabis and cannabinoid signaling research.

What this study cannot tell us

This is a perspective piece, not a systematic review. Reflects the priorities and viewpoint of US federal drug research leadership, which may not fully represent all stakeholder perspectives.

How to read the evidence

Authoritative perspective from federal research leadership, carrying significant weight for research direction but not providing new data.

When this study was published

2024 perspective

The bigger picture

The tension between rapidly expanding cannabis legalization and incomplete scientific knowledge is the central challenge identified. The endocannabinoid system offers both therapeutic opportunities and vulnerability to cannabis-related harm.

Questions still open

  • How will federal research priorities change if cannabis is rescheduled? Can the endocannabinoid system be targeted therapeutically without the risks of exogenous cannabis? What study designs can best address the developmental exposure question?

Common questions

What don't we know about cannabis?
According to NIDA leadership, major gaps include: the long-term effects of high-THC cannabis on the developing brain, how to leverage the endocannabinoid system for therapy, and effective treatments for cannabis use disorder.
Is cannabis research keeping up with legalization?
No. This NIDA perspective highlights that legalization has expanded faster than the science, particularly around high-potency products and exposure during critical brain development periods.

Read the original research

Cannabis and Cannabinoid Signaling: Research Gaps and Opportunities.

The Journal of pharmacology and experimental therapeutics, 391(2), 154-158

Citation

Valentino, Rita J; Volkow, Nora D. (2024). Cannabis and Cannabinoid Signaling: Research Gaps and Opportunities.. The Journal of pharmacology and experimental therapeutics, 391(2), 154-158. https://doi.org/10.1124/jpet.124.002331

Explore the wider topic